Cross-Sector entity
American Airlines Group is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. That works out to roughly 0.5 stories per week across a 39-day span. The busiest single day carried 2. Coverage clusters in earnings, which accounts for 1 of those 3, with the remainder spread across 2 other categories.
3 verified stories tracked
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
American Airlines Group is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. That works out to roughly 0.5 stories per week across a 39-day span. The busiest single day carried 2. Coverage clusters in earnings, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 10.7 original sources on average. We currently track 3 Cross-Sector stories that mention Eli Lilly & Co., published between June 28, 2026 and August 5, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eli Lilly & Co.. Shared-story counts are live from our verified record — not editorial picks.
CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Source: rttnews.com · finanznachrichten.de
Despite nearly 66% of S&P 500 stocks climbing, the index posted its second losing week in 13 as heavy selling in AI megacaps like Micron completely negated the broad market rally. Oil prices dropped to pre-Iran crisis levels, boosting transportation and healthcare stocks, while Eli Lilly soared 7.1% on European drug approvals.
Artificial intelligence stocks faced intense selling pressure on June 26, with Micron Technology plunging 6.7% despite its stock roughly quadrupling this year, highlighting growing investor skepticism about the sustainability of AI-driven valuations. The broad sell-off in AI names single-handedly dragged the S&P 500 to its second losing week in 13, even as most other stocks rose.
Source: pottsmerc.com · journal-advocate.com
